Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma lung disease: appropriate management.

D A Brown1, S N Breit

  • 1Centre for Immunology, St Vincent's Hospital and University of New South Wales, Sydney, Australia.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors influencing initial implementation of an online community-based exercise intervention with adults living with HIV: a systems approach.

Frontiers in rehabilitation sciences·2023
Same author

Empowering patients and educating staff - An online solution for the COVID era and beyond!

Annals of medicine and surgery (2012)·2021
Same author

The Global Task Force for Chronic Pain in People with HIV (PWH): Developing a research agenda in an emerging field.

AIDS care·2021
Same author

Prospects for observing and localizing gravitational-wave transients with Advanced LIGO, Advanced Virgo and KAGRA.

Living reviews in relativity·2020
Same author

Characterization of transient noise in Advanced LIGO relevant to gravitational wave signal GW150914.

Classical and quantum gravity·2020
Same author

GW150914: First results from the search for binary black hole coalescence with Advanced LIGO.

Physical review. D. (2016)·2020
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Scleroderma lung disease, including pulmonary hypertension, has limited treatment options. New localized therapies show promise for managing scleroderma

Area of Science:

  • Rheumatology and Pulmonology
  • Rare autoimmune diseases
  • Scleroderma and its complications

Background:

  • Scleroderma frequently affects the lungs through interstitial lung disease, pulmonary vascular disease, and bronchiolitis.
  • Pulmonary hypertension is the primary cause of mortality in scleroderma patients.
  • Controlled treatment trials for scleroderma-associated lung diseases are scarce.

Purpose of the Study:

  • To review current understanding and therapeutic approaches for lung involvement in scleroderma.
  • To discuss the challenges and future directions in managing scleroderma-related pulmonary conditions.

Main Methods:

  • Review of uncontrolled studies and pathological understanding of scleroderma.
  • Analysis of current treatment strategies for interstitial and pulmonary vascular disease.

Related Experiment Videos

  • Exploration of emerging therapeutic options, including locally administered therapies.

    • Main Results:

    • Progressive interstitial lung disease is often managed with immunosuppressants like cyclophosphamide and prednisone.
    • Pulmonary vascular disease in scleroderma carries a poor prognosis with limited current therapies.
    • Locally administered therapies are emerging as a promising strategy to mitigate systemic drug side effects.

    Conclusions:

    • Treatment for scleroderma's lung manifestations relies on rational choices based on limited evidence.
    • Pulmonary vascular disease management requires further research and novel therapeutic development.
    • Locally administered treatments offer potential for improved safety and efficacy in scleroderma lung disease.